Study of BGB-B2033 with other drugs for advanced solid tumors
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new drug called BGB-B2033, alone or with other drugs (tislelizumab and bevacizumab), in people with certain advanced cancers. The goal is to see if this combination can shrink tumors or slow their growth, and to check its safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these cancers: liver cancer (HCC), stomach cancer with high AFP levels, germ cell tumor, or squamous non-small cell lung cancer that shows GPC3.
- Your cancer must be advanced, locally advanced, or have spread, and cannot be removed with surgery.
- You must have at least one tumor that can be measured or evaluated by scans.
- You must be in good enough physical condition to be up and about (ECOG performance status 0 or 1).
- You must not have had prior treatment targeting GPC3 or 4-1BB.
- You must not have untreated or uncontrolled brain metastases, an active autoimmune disease, or be on high-dose steroids or immunosuppressive drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, BG-75098, alone or with other treatments, for adults with advanced solid tumors that have spread or cannot be removed. It may be an option if you have already tried standard treatments or if they are not suitable for you.
This study tests a new treatment (BGB-B2033) for advanced liver cancer that has returned or not responded to previous immune therapy. It compares this new drug to the standard options sorafenib or lenvatinib, which are targeted pills. The goal is to see if BGB-B2033 can help shrink or slow the cancer better than the current treatments.
This trial tests a new drug called BGB-26808, either by itself or with another drug called tislelizumab, for people with advanced solid tumors that have not responded to standard treatments or for whom no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests a new drug, BGB-B455, for people with advanced solid tumors that have not responded to other treatments. It focuses on tumors that have a specific marker called CLDN6, especially in ovarian cancer.
This early-phase trial tests a new drug called BG-C9074, either alone or with other cancer treatments, for people with certain advanced solid tumors that have not responded to standard therapy. The goal is to see if it is safe and effective.
This trial tests a new drug called BC2027 for people with advanced solid tumors that have a protein called GPC3. If standard treatments have stopped working, are not available, or caused side effects, this study may offer a new option.
Hear when a new Metastatic Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.